Theravance Biopharma Doses First Patient In Phase 2 Allergen Challenge Study Of TD-8236, An Investigational, Lung-Selective, Inhaled Pan-Janus Kinase Inhibitor For Inflammatory Lung Diseases
Benzinga Newsdesk